WO2022235045A1 - Her2 백신 조성물 - Google Patents
Her2 백신 조성물 Download PDFInfo
- Publication number
- WO2022235045A1 WO2022235045A1 PCT/KR2022/006317 KR2022006317W WO2022235045A1 WO 2022235045 A1 WO2022235045 A1 WO 2022235045A1 KR 2022006317 W KR2022006317 W KR 2022006317W WO 2022235045 A1 WO2022235045 A1 WO 2022235045A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- her2
- icd
- vaccine
- dna
- antigen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 55
- 229960005486 vaccine Drugs 0.000 title description 92
- 101150029707 ERBB2 gene Proteins 0.000 title description 2
- 239000000427 antigen Substances 0.000 claims abstract description 76
- 102000036639 antigens Human genes 0.000 claims abstract description 76
- 108091007433 antigens Proteins 0.000 claims abstract description 76
- 230000005847 immunogenicity Effects 0.000 claims abstract description 64
- 238000002255 vaccination Methods 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 40
- 108010041986 DNA Vaccines Proteins 0.000 claims abstract description 36
- 229940021995 DNA vaccine Drugs 0.000 claims abstract description 36
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 16
- 230000009257 reactivity Effects 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 38
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 34
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 18
- 229960000575 trastuzumab Drugs 0.000 claims description 11
- 238000011460 HER2-targeted therapy Methods 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 238000010998 test method Methods 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 239000002773 nucleotide Chemical group 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011238 DNA vaccination Methods 0.000 abstract description 8
- 108020004414 DNA Proteins 0.000 description 42
- 206010006187 Breast cancer Diseases 0.000 description 35
- 208000026310 Breast neoplasm Diseases 0.000 description 34
- 239000002246 antineoplastic agent Substances 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000028993 immune response Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 230000007774 longterm Effects 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102000015694 estrogen receptors Human genes 0.000 description 9
- 108010038795 estrogen receptors Proteins 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000005867 T cell response Effects 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000002688 persistence Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007390 skin biopsy Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- -1 small molecule compound Chemical class 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 2
- 101150054472 HER2 gene Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010022095 Injection Site reaction Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 238000012338 Therapeutic targeting Methods 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 108700020302 erbB-2 Genes Proteins 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010024405 HER2 peptide (369-377) Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940030749 prostate cancer vaccine Drugs 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940004212 yondelis Drugs 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to a HER2 vaccine composition.
- DFC Disease Free Survival
- ER-targeted therapeutics such as tamoxifen, which inhibit the activation of estrogen receptors
- HER2-positive patients various targeted therapies such as using a HER2-targeting antibody such as Trastuzumab are used to treat breast cancer or to slow the progression of breast cancer.
- Cancer vaccines are designed to activate cytotoxic T cells, causing the activated T cells to recognize and act against certain types of cancer cells, or to induce the production of antibodies that bind antigens present on the surface of cancer cells.
- prostate cancer vaccine sipuleucel-T Provenge®
- antigens are specifically expressed in certain types of tumor cells, each individual expresses antigens at a low level, or in the case of metastatic tumors, the antigen profile may change between the initially occurring tumor and metastatic tumor.
- the immune evasion mechanism of tumor cells is also explained as the cause of some low success rates.
- HER2/neu (hereinafter referred to as 'HER2') is a family of epidermal growth factor receptor (EGFR2), and overexpression of EGFR is observed in many carcinomas. In particular, HER2 overexpression is observed in 15-30% of all breast cancer patients, and HER2 expression is known to be associated with recurrence and poor prognosis in breast cancer patients.
- HER2 is a transmembrane protein having the amino acid sequence of SEQ ID NO: 1, an intracellular domain (ICD, HER2 aa 676-1255) having protein tyrosine kinase activity, a transmembrane domain: TM, HER2 aa 653-675 ) and an extracellular domain (ECM, HER2 aa 22-652).
- HER2 in breast cancer has been studied quite extensively, and several immunogenic peptides have been discovered.
- immunotherapy is attempted, such as re-injection after loading into dendritic cells.
- no clinically significant therapeutic or protective effects were reported in women with advanced breast cancer.
- the recent large-scale Phase 3 clinical trial was discontinued because there was no difference in disease-free survival (DFS) compared to the placebo group.
- DFS disease-free survival
- Examples of another HER2 peptide vaccine include HER2-ICD peptide vaccine AE37 (LRMK-GVGSPYVSRLLGICL: LRMK-HER2 aa 776-790)), HER2-TM peptide vaccine GP2 (HER2 aa 654-662), and the like.
- HER2-ICD peptide vaccine AE37 LRMK-GVGSPYVSRLLGICL: LRMK-HER2 aa 776-790
- HER2-TM peptide vaccine GP2 HER2 aa 654-662
- Vaccines for disease treatment are often administered twice or more repeatedly with a specific cycle due to their characteristics, and long-term immunogenicity using the subject's immune system must be generated.
- a DNA vaccine composition comprising a plasmid comprising a nucleic acid sequence encoding HER2-ICD was stably immunogenic against HER2-ICD antigen in breast cancer patients without side effects.
- the present invention was completed by discovering a patient group showing long-term immunogenicity to the vaccine composition as well as improving it.
- An object of the present invention is to provide a method for predicting the acquisition of immunogenicity and therapeutic effect for a DNA vaccine through a method of testing immunogenicity for a vaccine antigen (HER2-ICD antigen) before DNA vaccination do it with
- an object of the present invention is to provide a method for enrichment of DNA vaccination targets through a method of obtaining immunogenicity and predicting the therapeutic effect of the DNA vaccine of the present invention.
- an object of the present invention is to provide an information providing method for selecting a patient who will acquire immunogenicity and therapeutic effect in a DNA vaccine through the method of selecting the target for DNA vaccination.
- the present invention predicts the acquisition of immunogenicity and therapeutic effect (efficacy) of the DNA vaccine through a method of testing the immunogenicity for the vaccine antigen (HER2-ICD antigen) before DNA vaccination.
- a target (patient group) to be vaccinated with DNA may be selected.
- the method of obtaining immunogenicity and predicting the therapeutic effect of the DNA vaccine (HER2-ICD DNA vaccine) is a method of obtaining the immunogenicity of a DNA vaccine before DNA vaccination without a great burden on the patient and In addition to predicting the therapeutic effect (efficacy), there is an effect of being able to select a subject (patient group) to be vaccinated that can obtain immunogenicity and therapeutic effect (efficacy) for the DNA vaccine.
- prevent refers to the success or signs of success in preventing breast cancer recurrence/relapse when a patient in clinical remission is examined by radiation or physical methods.
- no recurrence refers to a state in which there is no recurrence of cancer in breast cancer or other sites when a patient in clinical remission is examined by radiation or physical methods.
- cancer to breast cancer or other sites after a period of improvement, remission, or remission by breast cancer treatment. means a sign or symptom of an outbreak.
- immunogenicity refers to the ability of a particular substance, such as an antigen, to elicit an immune response in a subject. As used herein, it refers to the ability to induce an immune response to the HER2-ICD antigen, and the immune response is stimulated with the HER2-ICD antigen in PBMCs isolated from the subject by the ELISpot method for interferon gamma (IFN- ⁇ ELISPOT). ), but is not limited thereto.
- the amount of IFN- ⁇ produced by peripheral blood mononuclear cells (PBMC) stimulated by HER2-ICD is measured by the ELISpot method (Enzyme-linked immuno-spot assay: ELISpot).
- ELISpot Enzyme-linked immuno-spot assay: ELISpot.
- immune response refers to a physiological response by the immune system of a subject to an antigen, and as a result of this immune response herein, refers to, but is not limited to, protective immunity against a HER2-ICD antigen.
- protective immunity means that a subject initiates an immune response against a HER2-ICD antigen so that the subject's immune system can target and destroy cells expressing the same antigen, thereby causing cancer recurrence or It is meant to reduce cancer progression.
- protective immunity is conferred by, but not limited to, T lymphocytes.
- PBMC peripheral blood mononuclear cells
- booster refers to a dose of an immunogen administered to a patient to enhance, prolong or maintain protective immunity and to overcome down-regulation of T-cell responses mediated by regulatory T-cells.
- pharmaceutically acceptable refers to a substance that is acceptable to a patient from a pharmacological/toxicological point of view with respect to composition, formulation, safety, etc.
- pharmaceutically acceptable carrier refers to the biological activity of the active ingredient(s). It refers to a medium that does not interfere with the effect and is nontoxic to the subject upon administration.
- patient refers to a living organism suffering from, treated, or susceptible to a condition for which the disease can be prevented or treated by administration of a vaccine composition of the present invention, such as breast cancer, includes both humans and animals.
- Subjects include, but are not limited to, mammals (eg, mice, monkeys, horses, cattle, pigs, dogs, cats, etc.), preferably humans.
- patient or “subject” in the present invention includes, without distinction, a breast cancer patient or a breast cancer patient expressing HER2.
- administering refers to introducing a vaccine composition to a subject using any of a variety of methods and delivery systems known in the art.
- routes of administration include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, such as by injection or infusion.
- administration refers to an intradermal mode of administration generally by injection, including intravenous, intramuscular, intraarterial, intrathecal, or intralymphatic injection and infusion, but It is not limited.
- Other parenteral routes include topical, epithelial, or mucosal routes of administration, such as intranasal, vaginal, rectal, or sublingual routes.
- the terms “vaccine injection”, “treatment” and “vaccination” to a subject are used without distinction.
- the term “immune anticancer agent” refers to a therapeutic agent that induces immune cells to selectively attack only cancer cells by stimulating the immune system by injecting artificial immune proteins into the body, unlike conventional anticancer agents that attack cancer itself. It is an anticancer drug with a mechanism to restore or strengthen the tumor recognition or destruction ability of the immune system in order to overcome the immunosuppression or immune evasion mechanism acquired by spores.
- the immune anticancer agent includes, but is not limited to, an immune checkpoint inhibitor, an immune cell therapeutic agent, and an immunoviral therapeutic agent.
- the term “immune checkpoint inhibitor” refers to an immune checkpoint protein involved in T cell suppression when some cancer cells avoid immunity while utilizing the immune checkpoint of T cells, which are immune cells in the body. It is a type of immunotherapy that blocks activation to activate T cells to attack cancer cells, including CTLA-4 inhibitors, PD-1 inhibitors, LAG-3 inhibitors, TIM-3 inhibitors, TIGIT inhibitors, and VISTA inhibitors. It is not limited thereto.
- the immune checkpoint inhibitor is an antagonist, and may be an antagonist antibody or a small molecule compound.
- therapeutic targeting HER2 refers to a treatment by a mechanism that inhibits the activity of the HER2 protein, and refers to a treatment using a drug that blocks the active domain of HER2.
- specific examples of the drug may include therapeutic antibodies, small molecules, and drug-conjugated antibody-drug conjugates (ADCs) that have antagonistic action against HER2.
- ADCs drug-conjugated antibody-drug conjugates
- An example of a representative antagonist antibody includes, but is not limited to, trastuzumab.
- therapeutic targeting HER2 and "HER2 targeting therapy” are used without distinction.
- compositions disclosed herein are prepared as DNA vaccines.
- a DNA vaccine comprises a plasmid having a promoter, appropriate transcriptional and translational control elements and a nucleic acid sequence encoding one or more polypeptides of the present invention.
- the plasmid may additionally contain enhancement sequences, eg, sequences that enhance expression levels, intracellular targeting, and the like.
- the antigen of the vaccine composition of the present invention is an intracellular domain (ICD) of aa 676-1255 of the HER2 gene (HER2-ICD).
- the polypeptide sequence of HER2-ICD has 100% homology to the amino acid sequence of SEQ ID NO: 2, or, otherwise, 99% or more, 95% or more, 90% or more, 85% or more, or 80% or more homology can have However, if the homology is limited to the above specific value, the immunogenicity to the HER2-ICD antigen due to vaccination has the same or equivalent effect as the sequence having 100% homology.
- the DNA vaccine comprises a plasmid vector comprising a nucleic acid sequence encoding the HER2-ICD of the present invention.
- the plasmid is a pUMVC3 (conventional name is 'pNGVL3', so the two names may be used interchangeably) plasmid.
- the nucleic acid sequence encoding the HER2-ICD has 100% homology to the nucleic acid sequence of SEQ ID NO: 3 or, otherwise, 99% or more, 95% or more, 90% or more, 85% or more, 80% or more homology can have However, if the homology is limited to the above specific value, the immunogenicity to the HER2-ICD antigen due to vaccination has the same or equivalent effect as the sequence having 100% homology.
- the DNA vaccine may additionally encode immunomodulatory molecules that modulate the resulting immune response, such as enhancing the efficacy of the vaccine, stimulating the immune system or reducing immunosuppression. have.
- the patient group to which the HER2-ICD DNA vaccine composition is administered is a group of patients with stage 3 or 4 breast cancer, and is a group of patients expressing HER2.
- Each patient was in complete remission after completing standard breast cancer treatment, or only stable bone only diseas (SBO) was allowed in the stage 4 breast cancer patient group.
- the vaccine composition in the present invention aims to induce and/or maintain protective immunity against breast cancer recurrence, in the present invention, it can be administered on any schedule suitable for inducing and/or maintaining a cytotoxic T cell response to the HER2-ICD antigen.
- the vaccine composition of the present invention may be administered to a patient.
- a vaccine composition as described and exemplified herein as a primary vaccination may be administered to a patient on a schedule, followed by administration of a booster to induce and/or maintain protective immunity.
- the vaccine composition may be administered to the patient once, twice or more times per month.
- the booster may be administered singly or multiple times at regular intervals, for example, at intervals of 1 month, and may be administered singly or multiple times with a period of 6 months or more.
- the HER2-ICD vaccine was administered three times once a month as the primary inoculation, but an additional booster may be administered after 6 months or 1 year.
- the booster may have the same dose and composition as the vaccine composition used for the primary inoculation, or the dose and/or composition may be changed.
- dose refers to the total amount of the active ingredient (HER2-ICD plasmid DNA) of the vaccine composition administered once to a subject.
- the dose of the HER2-ICD DNA vaccine composition was selected and administered to three arms of 10 ⁇ g, 100 ⁇ g, and 500 ⁇ g per arm (22 patients group). In each arm, immunogenicity to HER2-ICD antigen was observed to increase with vaccine administration, and all vaccine-related adverse events occurring in each arm were Grade 1 and 2 (extremely low grade) and Grade 3-5 serious. No side effects were found. There was no statistically significant difference between each arm regarding side effects.
- the DNA vaccine composition of the present invention is a vaccine using HER2-ICD as an antigen, and is different from the sequence of HER2-ECD or peptide, but it is not effective against HER2-ECD in the patient group administered with the vaccine composition of the present invention, especially in the Arm 2 and Arm 3 patient groups. Immune reactivity was also increased.
- the immunoreactivity to HER2-ICD persists for a long time even after vaccine administration is finished, and the vaccine composition of the present invention has an excellent effect in preventing recurrence or metastasis of breast cancer in the patient group in remission with breast cancer treatment.
- the total amount of HER2-ICD plasmid DNA contained in the vaccine administered once is 10 ⁇ g to 1000 ⁇ g, 20 ⁇ g to 1000 ⁇ g, 30 ⁇ g to 1000 ⁇ g, 40 ⁇ g to 1000 ⁇ g, 50 ⁇ g to 1000 ⁇ g, 60 ⁇ g to 1000 ⁇ g, 70 ⁇ g to 1000 ⁇ g, 10 ⁇ g to 900 ⁇ g, 20 ⁇ g to 900 ⁇ g, 30 ⁇ g to 900 ⁇ g, 40 ⁇ g to 900 ⁇ g, 50 ⁇ g to 900 ⁇ g, 60 ⁇ g to 900 ⁇ g, 70 ⁇ g to 900 ⁇ g, 10 ⁇ g to 800 ⁇ g, 20 ⁇ g to 800 ⁇ g, 30 ⁇ g to 800 ⁇ g, 40 ⁇ g to 800 ⁇ g, 50 ⁇ g to 800 ⁇ g, 60 ⁇ g to 800 ⁇ g , 70 ⁇ g to 800 ⁇ g, 10 ⁇ g to 700 ⁇ g, 20 ⁇ g to
- the desired immune response may not occur. This could rather be reduced.
- predicting immunoreactivity is of paramount importance. Because, in general, a vaccine requires repeated administration of two or more times, and since the purpose of the vaccine is to obtain long-term immunogenicity, a long period of time is required to confirm the effectiveness of the vaccine.
- the HER2-targeting treatment showed little immunogenicity to the HER2-ICD antigen at baseline in the patient group (Naive group) who had never received HER2-targeting treatment.
- Direct therapy (trastuzumab is prescribed in the present invention) has been completed (Prior treatment) or exposure to a treatment targeting HER2, such as concurrent treatment during the vaccination period It was confirmed that the immunogenicity against the HER2-ICD antigen at baseline was increased in the patient group with previous experience.
- DNA acts as a continuous source for transfecting cells at the site of vaccine administration to produce the desired antigen. Therefore, when DNA is continuously present at the site of vaccine administration for a long period of time, antigen can be continuously produced, which is thought to be helpful in maintaining antigen-specific immunity. If it persists for a long time, the subject may elicit an immune response against the plasmid DNA itself.
- the vector DNA was detected in 31 patients, It was not detected in 21 patients.
- the group of 21 patients in which vector DNA was not detected showed a tendency to increase in immunoreactivity to the HER2-ICD antigen compared to patients in which vector DNA was detected. , in particular, it was confirmed that there was a significant difference in immunoreactivity at LTFU (12 months after completion of vaccination).
- the vaccine composition described in the specification of the present invention is a pharmaceutically acceptable excipient, carrier, diluent, buffer, stabilizer, preservative, adjuvant ( adjuvant) or other substances well known in the art. These substances are non-toxic and do not interfere with the pharmaceutical activity of the active ingredient(s).
- the pharmaceutical carrier or diluent may be, for example, an aqueous solution.
- the carrier or other material that may be included in the vaccine composition of the present invention may be selected differently depending on the route of administration (eg, oral, intravenous, dermal or subcutaneous, nasal, intramuscular, intradermal and intraperitoneal administration).
- the vaccine composition of the present invention may include one or more “pharmaceutically acceptable carriers”. These typically include proteins, saccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose, and trehalose. Such carriers are well known in the art.
- the vaccine composition may also contain a diluent such as water, saline, glycerol, and the like.
- auxiliary substances such as wetting or emulsifying agents, pH buffer substances and the like may be present.
- Phosphate-buffered saline without sterile pyrogens and tromethamine (Tris) are typical carriers.
- One aspect of the present invention relates to a vaccine composition or kit as described above comprising one or more plasmid DNAs as an active ingredient. They may be for use in a method of inducing an immune response in a subject, or providing treatment, vaccination or immunotherapy, and the vaccine composition may be a vaccine or immunotherapeutic composition. Such treatment or vaccination comprises administering to the subject a vaccine composition of the present invention.
- the vaccine composition may be administered to a subject on a fixed schedule.
- the vaccine composition of the present invention may be lyophilized or may be in aqueous form, for example an aqueous solution or suspension. Liquid formulations of this type are ideal for injection as they can be administered directly in packaged form without the need for the composition to be reconstituted in an aqueous medium.
- the vaccine composition may be provided in vials or may be provided in a prefilled syringe. The syringe may be supplied with or without a needle. A syringe contains a single dose, whereas a vial may contain a single dose or multiple doses.
- the vaccine composition of the present invention may be administered using a microneedle.
- the vaccine composition of the present invention may be formulated as a delayed release vehicle or depot preparation.
- Such long acting formulations may be administered by inoculation or implantation (eg subcutaneously or intramuscularly) or by injection.
- a vaccine composition may be formulated with a suitable polymeric or hydrophobic material (e.g., an emulsion in an acceptable oil) or ion exchange resin, or as a sparingly soluble derivative (e.g., a sparingly soluble salt).
- a suitable polymeric or hydrophobic material e.g., an emulsion in an acceptable oil
- ion exchange resin e.g., a sparingly soluble derivative
- Liposomes and emulsions are well-known examples of delivery vehicles suitable for use as carriers.
- the vaccine composition of the present invention may contain an antimicrobial agent when packaged in a multiple dose format.
- the antibacterial agent may be selected from 2-phenoxyethanol or parabens (methyl, ethyl, propyl paraben).
- Optional preservatives are preferably present at low levels.
- a preservative may be added exogenously and/or may be a component of the bulk antigen that is mixed to form the composition.
- the vaccine composition of the present invention may be provided in the form of a kit including instructions and the like.
- the vaccine composition of the present invention may contain one or more adjuvants to increase the immunogenicity of the composition.
- Such suitable adjuvants include aluminum salts such as aluminum hydroxide or aluminum phosphate, but may be salts of calcium, iron or zinc or may be insoluble suspensions of acylated tyrosine or acylated sugars, or may be cationic or anionic It may be selected from derivatized saccharides and the like, but is not limited thereto.
- the adjuvant may contain cytokines used as immunomodulatory agents.
- Cytokines suitable for use as the immunomodulatory agent include interleukins (eg, IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.); Although it can be selected from macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), granulocyte macrophage colony stimulating factor (GM-CSF), etc. , but not limited thereto.
- interleukins eg, IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.
- M-CSF macrophage colony stimulating factor
- TNF tumor necrosis factor
- GM-CSF granulocyte macrophage colony stimulating factor
- GM-CSF may be included as an adjuvant.
- the adjuvant may be added in an amount of 0.075 mg to 0.2 mg, or 0.08 mg to 0.12 mg per dose.
- the vaccine composition of the present invention may be administered in combination with one or more anticancer agents selected from chemical anticancer agents, targeted anticancer agents, and immune anticancer agents.
- One or more anticancer agents selected from chemical anticancer agents, targeted anticancer agents, and immune anticancer agents that can be administered in combination with the vaccine composition of the present invention may be administered simultaneously or sequentially with a time difference, and may be selected according to an appropriate time and cycle. .
- the chemical anticancer agent is also called a cytotoxic anticancer agent or a chemical drug anticancer agent.
- the chemical anticancer agent for example, gemcitabine (Gemcitabine) (jecitabine), cytarabine (Cytarabine), carboplatin (Carboplatin) (paraplatin), cisplatin (Cisplatin) (platinol, platinum-AQ) ), Crizotinib (Zalkori), Cyclophosphamide (Cytoxane, Neosar), Docetaxel (Taxotere), Doxorubicin (Adriamycin), Etoposide ) (bepeside), fluorouracil (5-fluorouracil, 5-FU), irinotecan (camptosar), liposome-encapsulated doxorubicin (doxyl), methotrexate (polex, mexate, ametope) Terine), Paclitaxel (Taxol) (je
- the target anticancer agent is trametinib, vemurafenib, alpelisib, dactolisib, gefitinib, erlotinib, lapatinib ( Lapatinib), Sunitinib, Sorafenib, Crizotinib, Dabrafenib, Trastuzumab, Cetuximab, Bevacizumab , Panitumumab, Ipilimumab, Pertuzumab, Tofacitinib, Imatinib, Bortezomib, Ofatumumab and Alemtuzumab ( Alemtuzumab) may be one or more targeted therapeutic agents selected from the group consisting of, but is not limited thereto.
- the immunocancer agent is CTLA-4 (cytotoxic Tlymphocyte-associated protein 4), PD-1 (Programmed cell death protein 1), LAG3 (Lymphocyte Activation Gene-3), TIM-3 (T-cell Immunoglobulin and Mucin-domain containing-3), TIGIT (T-cell Immunoreptor with IG and ITIM domain), and VISTA (Vdomain Ig Suppressor of T cell Activation) to any one selected from the group consisting of an immune checkpoint inhibitor (immune checkpoint inhibitor)
- an immune checkpoint inhibitor immunoreconstituted thereto.
- the composition may further include an anticancer adjuvant, and more preferably, the anticancer adjuvant may be a STimulator of InterferoN Gene (STING) agonist, but is not limited thereto.
- STING STimulator of InterferoN Gene
- administration of the HER2-ICD DNA vaccine composition may be performed simultaneously with treatment with other cancer therapeutic agents.
- the cancer treatment agents include anticancer agents such as fluorouracil, doxorubicin, and paclitaxel that are standardly used for breast cancer treatment, Trastuzumab, Herceptin®, an antibody treatment for HER2, and tamoxifen, an Estrogen receptor (ER) targeted treatment ) or bisphosphonates may be used, but are not limited thereto.
- stage 3 or 4 breast cancer patients who met the following criteria.
- stage IV patients (2) Cases that are found to overexpress HER2 gene or protein in the primary tumor or metastasis stage through immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).
- ECOG performance score is 0 (SCOG Performance Score O).
- WBC White Blood Cell
- WBC Do not receive chemotherapy or other immunosuppressive drugs such as steroids for 30 days prior to clinical trial enrollment.
- LVEF Left Ventricular Ejection Fraction
- Standard of care including bisphosphonates, anti-estrogens and Trastuzumab therapy, was permitted during the vaccination period. All patients provided written informed consent in accordance with institutional and federal regulations. 66 patients were enrolled from May 2004 to August 2007 and 64 patients completed all three vaccinations. Two patients enrolled in Arm 1 discontinued the study due to disease progression after one dose of vaccine. Long-term toxicity of patients was followed for 10 years in accordance with federal regulations.
- Toxicity was graded according to CTCAE v 3.0 and vaccine-related toxicity was defined as an Adverse Effect, regardless of severity, definitely, probably or possibly. Long-term adverse events were assessed through an annual medical record review of surviving patients.
- PBMCs were evaluated at baseline and after the third vaccine administration (12 weeks) and 1, 3, 6 and 12 months after the last vaccination (after clinical enrollment, respectively) to evaluate the induced immune responses to HER2-ICD and HER2-ECD. 16, 24, 36, and 60 weeks).
- PBMCs were assessed for the presence of plasmid DNA at baseline and 1 month after the last vaccine.
- the HER2-ICD sequence (SEQ ID NO: 2) was inserted into pNGVL3 and confirmed by DNA sequencing.
- the plasmid DNA vaccine, pNGVL3-HER2-ICD was amplified, quantified and prepared in vials under GMP conditions.
- Single dose vials contained 10 ⁇ g, 100 ⁇ g or 500 ⁇ g plasmid DNA (pNGVL3-HER2-ICD) suspended in Tromethamine/EDTA as stabilization buffer (1.2 ml) and commonly 100 ⁇ g GM-CSF.
- Vials were tested for microbial, sterility, and stability and stored between -25 o C and -10 o C at the University of Washington Investigational Drug Services Pharmacy according to US Pharmacopoeia standards.
- PBMC samples from all patients were processed and cryopreserved using standardized methods that have been demonstrated to preserve lymphocyte function. All samples for each patient were thawed and analyzed simultaneously to reduce experimental variability. Specificity for HER2 through the IFN- ⁇ Elispot method stimulated by an antigen (stimulator) to be described later according to the previously known method of Disis et al. (J Clin Oncol. 2009 Oct 1; 27(28): 4685-92) negative response was measured. For the HER2-ICD antigen or HER2-ECD antigen (stimulator), an overlapping 15 amino acid peptide pool (1 mg/mL) of 11 amino acids was used as an antigen.
- a patient was considered to have an increased HER2-ICD antigen-specific T cell response if the HER2-ICD antigen-specific IFN- ⁇ production in PBMCs measured by the Elispot method after vaccination was doubled from the baseline.
- the vaccination was administered between the two tattoo marks.
- a biopsy was performed at the designated inoculation site (skin) at the designated period.
- the isolated skin tissue was stored at 70 ° C.
- DNA of tissue and PBMC was isolated using a DNA isolation kit, and vector DNA was amplified using a primer pair of PRDM36 primer [GACTAACAGACTGTTCCTTTCCATGG: coding primer] and PRDM52 primer [GCCAGAAGTCAGATGCTCAA: complementary primer].
- Arm 1 and Arm 3 each consisted of 22 patients, each containing 10 ⁇ g, 100 ⁇ g, and 500 ⁇ g of HER2-ICD plasmid DNA, and a vaccine composition containing 100 ⁇ g of GM-CSF in common. It was administered intradermally. The patient characteristics for each arm are listed in Table 1.
- Estrogen Receptor PR Progesterone Receptor
- the side effects caused by the administration of the vaccine composition of the present invention cannot be said to be of concern when administered to a subject at an extremely low grade, and no signs of autoimmune disease or the occurrence of disease were observed.
- the vaccine composition of the present invention was not observed to be inserted into the genome of the subject, it is judged that there is no problem in safety in clinical application.
- Anti-ds DNA anti-double strand DNA antibody
- the immunoreactivity to the HER-ICD antigen in PBMCs prior to vaccination was evaluated by the Elispot method for interferon gamma ( IFN- ⁇ ELISPOT). In addition, this value was used as a criterion to calculate the change in immunoreactivity to HER2-ICD antigen after vaccination.
- the Naive group Prior to vaccination, the Naive group, who had no experience in HER2-direct therapy (trastuzumab was prescribed in this study), and Prior who completed HER2-targeted therapy before vaccination group, and concurrent group receiving HER2 target treatment during vaccination.
- 1:1000000, 1:9707, and 1:12840 in each group are median values measured by the Elispot method.
- the values in the naive group showed a statistical difference from the values in the Prior and Concurrent groups, but the Prior and Concurrent groups There was no statistical difference between the values of
- the HER2-ICD antigen As a result of analyzing the immunoreactivity to the HER2-ICD antigen in PBMCs isolated at 1 month and 12 months (Long Term Follow-up: LTFU) based on the completion of the subsequent vaccination, surprisingly, at baseline, the HER2-ICD antigen In patients who did not show immunogenicity, it was confirmed that the immune response to the HER2-ICD antigen increased to a high level (more than two-fold), and the level of the immune response was maintained until LTFU. In addition, the patients who did not show immunogenicity to the HER2-ICD antigen at the baseline include most of the naive patients, and some of the patients who received HER2-targeted therapy.
- the immunogenicity to the HER2-ICD antigen is In this case, even if the HER2-ICD DNA vaccine was vaccinated, there were few patients with more than two-fold increase in immunogenicity and/or long-term maintenance.
- HER2-targeted treatment for the patient group to be vaccinated Patients who have never received HER2-ICD antigen or who have received HER2-targeted therapy can be selected as a group of patients with little or no immunogenicity to the HER2-ICD antigen at baseline before vaccination (specification based on clinical criteria) and pre-enrichment.
- Skin biopsies were obtained from a total of 52 patients, and vector DNA was detected in 31 (60%) of them. Vector DNA was detected in 61% of patients on Arm 1, 50% on Arm 2, and 73% on Arm 3.
- SEQ ID NO: 1 (HER2 full length sequence)
- SEQ ID NO: 2 (HER2-ICD amino acid sequence)
- SEQ ID NO: 3 (HER2-ICD nucleotide sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
DNA 백신 용량 | Arm 1 (10㎍) |
Arm 2 (100㎍) |
Arm 3 (500㎍) |
|||
No. | % | No. | % | No. | % | |
연령(~세): 중간값(범위) | 50(38-68) | 51(34-72) | 53(42-77) | |||
병기 | ||||||
III | 15 | 68 | 15 | 68 | 12 | 55 |
IV (NED) | 3 | 14 | 4 | 18 | 7 | 32 |
IV (SBO) | 4 | 18 | 3 | 14 | 3 | 14 |
ER/PR 상태 | ||||||
ER+ 및/또는 PR+ | 14 | 64 | 15 | 68 | 8 | 36 |
ER-/PR- | 8 | 36 | 7 | 32 | 14 | 64 |
이전 트라스투주맙 치료여부 | ||||||
No | 4 | 18 | 2 | 9 | 2 | 9 |
Yes | 18 | 32 | 20 | 91 | 20 | 91 |
동시 트라스투주맙 치료 | ||||||
No | 14 | 64 | 12 | 55 | 9 | 41 |
Yes | 8 | 36 | 10 | 45 | 13 | 59 |
DNA 백신 용량 | total | Arm 1 (10㎍) |
Arm 2 (100㎍) |
Arm 3 (500㎍) |
|||||
No | % | No | % | No | % | No | % | ||
가장 빈번한 부작용(n=188) | |||||||||
주사부위 반응 | 117 | 23 | 38 | 7 | 48 | 9 | 31 | 6 | |
감기 유사 반응 | 35 | 7 | 19 | 4 | 9 | 2 | 7 | 1 | |
피로 | 36 | 7 | 14 | 3 | 17 | 3 | 5 | 1 | |
비정상적인 자가 면역반응(n=16) | |||||||||
ANA | 11 | 2 | 4 | 1 | 3 | 1 | 4 | 1 | |
C3 | 5 | 1 | 3 | 1 | 1 | <1 | 1 | <1 | |
Anti-ds DNA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
모든 부작용의 등급(n=517) | |||||||||
1 | 459 | 89 | 180 | 35 | 130 | 25 | 149 | 29 | |
2 | 57 | 11 | 26 | 5 | 11 | 2 | 20 | 4 | |
3 | 1 | <1 | 0 | 0 | 0 | 0 | 1 | <1 | |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Time point | DNA negative | DNA positive | p-value | ||
N | Median(IQR) | N | Median(IQR) | ||
Baseline | 21 | 70 (7, 555) | 31 | 81 (4, 243) | 0.65a |
Week 12-baseline | 19 | 4 (-99, 292) | 30 | -1 (-61, 44) | |
Week 16-baseline | 20 | 16 (-25, 228) | 29 | 0 (-99, 17) | |
Week 24-baseline | 19 | 0 (-390, 215) | 28 | -1 (-187, 87) | |
Week 36-baseline | 18 | 25 (3, 301) | 28 | 14 (-86, 240) | |
Week 60-baseline | 17 | 36 (-122, 417) | 27 | 0 (-31, 249) | 0.02b |
Claims (8)
- HER2-ICD(세포내 영역: intracellular domain) DNA 백신을 접종받을 환자의 말초혈액단핵구(PBMC)에서 백신 접종 전 HER2-ICD 항원에 대한 면역원성을 검사하는 방법을 포함하는, HER2-ICD DNA 백신의 반응성을 예측하는 방법.
- 제1항에 있어서,상기 HER2-ICD DNA 백신을 접종받을 환자는 HER2를 발현하는 암환자인, 방법.
- 제2항에 있어서,상기 HER2-ICD DNA 백신을 접종받을 환자는 백신 접종 전 HER2 표적 치료를 받은 경험이 없는, 방법.
- 제3항에 있어서,상기 HER2 표적 치료는 HER2에 대한 치료용 항체를 포함하는 약학적 조성물에 의한 것인, 방법.
- 제4항에 있어서,상기 HER2에 대한 치료용 항체는 트라스투주맙을 포함하는 약학적 조성물에 의한 것인, 방법.
- 제1항 내지 제5항의 방법 중 어느 한 항의 방법에 의해 HER2-ICD DNA 백신을 투여할 환자를 선별하는 방법.
- 제1항 내지 제5항 중 어느 한 항에 있어서,상기 HER2-ICD DNA 백신은 서열번호 2 또는 이와 80% 이상의 서열상동성을 지니는 HER2-ICD 영역을 암호화하는 뉴클레오티드 서열을 포함하는 플라스미드 벡터를 포함하는, 방법.
- 제7항에 있어서,상기 뉴클레오티드 서열은 서열번호 3 또는 이와 80% 이상의 서열상동성을 지니는, 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280032494.4A CN117280219A (zh) | 2021-05-04 | 2022-05-03 | Her2疫苗组合物 |
JP2023561907A JP2024515574A (ja) | 2021-05-04 | 2022-05-03 | Her2ワクチン組成物 |
EP22799088.4A EP4336187A1 (en) | 2021-05-04 | 2022-05-03 | Her2 vaccine composition |
KR1020237038646A KR20240006547A (ko) | 2021-05-04 | 2022-05-03 | Her2 백신 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163183869P | 2021-05-04 | 2021-05-04 | |
US63/183,869 | 2021-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022235045A1 true WO2022235045A1 (ko) | 2022-11-10 |
Family
ID=83932835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006317 WO2022235045A1 (ko) | 2021-05-04 | 2022-05-03 | Her2 백신 조성물 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4336187A1 (ko) |
JP (1) | JP2024515574A (ko) |
KR (1) | KR20240006547A (ko) |
CN (1) | CN117280219A (ko) |
WO (1) | WO2022235045A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020193329A1 (en) | 2000-08-14 | 2002-12-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies |
US20100332417A1 (en) * | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
KR101572474B1 (ko) | 2007-06-01 | 2015-11-30 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유방암 재발 예방용 백신 |
-
2022
- 2022-05-03 KR KR1020237038646A patent/KR20240006547A/ko active Search and Examination
- 2022-05-03 CN CN202280032494.4A patent/CN117280219A/zh active Pending
- 2022-05-03 WO PCT/KR2022/006317 patent/WO2022235045A1/ko active Application Filing
- 2022-05-03 EP EP22799088.4A patent/EP4336187A1/en active Pending
- 2022-05-03 JP JP2023561907A patent/JP2024515574A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020193329A1 (en) | 2000-08-14 | 2002-12-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies |
KR101572474B1 (ko) | 2007-06-01 | 2015-11-30 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유방암 재발 예방용 백신 |
US20100332417A1 (en) * | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
Non-Patent Citations (7)
Title |
---|
ARAB ATEFEH; YAZDIAN-ROBATI REZVAN; BEHRAVAN JAVAD: "HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, BIRKHAEUSER VERLAG AG, CH, vol. 68, no. 1, 9 January 2020 (2020-01-09), CH , XP036981915, ISSN: 0004-069X, DOI: 10.1007/s00005-019-00566-1 * |
BREAST CARE, vol. 11, 2016, pages 116 - 121 |
CLIN CANCER RES, vol. 25, no. 14, 15 July 2019 (2019-07-15) |
DISIS ET AL., J CLIN ONCOL, vol. 27, no. 28, 1 October 2009 (2009-10-01), pages 4685 - 92 |
LIMENTANI STEVEN A.; CAMPONE MARIO; DORVAL THIERRY; CURIGLIANO GIUSEPPE; BOER RICHARD DE; VOGEL CHARLES; WHITE SHANE; BACHELOT THO: "A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors", BREAST CANCER RESEARCH AND TREATMENT, SPRINGER US, NEW YORK, vol. 156, no. 2, 18 March 2016 (2016-03-18), New York, pages 319 - 330, XP035653637, ISSN: 0167-6806, DOI: 10.1007/s10549-016-3751-x * |
MARGARET K. CALLAHAN, PATRICK ALEXANDER OTT, KUNLE ODUNSI, STEPHANE V. BERTOLINI, LINDA S. PAN, RALPH RUDOLPH VENHAUS, JOYSON JOSE: "A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 32, no. 15, suppl., 1 January 2014 (2014-01-01), US , pages 1 - 2, XP002757851, ISSN: 0732-183X * |
OMABE MAXWELL, AHMED SHAHID, SAMI AMER, XIE YUFENG, TAO MIN, XIANG JIM: "HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy", WORLD JOURNAL OF VACCINES, SCIENTIFIC RESEARCH PUBLISHING, INC., US, vol. 05, no. 02, 1 January 2015 (2015-01-01), US , pages 106 - 128, XP093001309, ISSN: 2160-5815, DOI: 10.4236/wjv.2015.52013 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024515574A (ja) | 2024-04-10 |
KR20240006547A (ko) | 2024-01-15 |
EP4336187A1 (en) | 2024-03-13 |
CN117280219A (zh) | 2023-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220241389A1 (en) | Vaccine for the prevention of breast cancer relapse | |
US10450380B2 (en) | Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor | |
EP2613808B1 (en) | Companion animal cancer treatments with an anti p2x7 antibody | |
CA2744035C (en) | Vaccine for the prevention of breast cancer recurrence | |
AU2002322192B2 (en) | Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions | |
JP2003524021A (ja) | 悪性中皮腫の診断および治療のための組成物および方法 | |
AU2002322192A1 (en) | Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions | |
WO2022235045A1 (ko) | Her2 백신 조성물 | |
WO2023008815A1 (ko) | Her2 백신 조성물 | |
WO2022235046A1 (ko) | Her2 백신 조성물 | |
WO2022235044A1 (ko) | Her2 백신 조성물 | |
AU2015203572B2 (en) | Vaccine for the Prevention of Breast Cancer Recurrence | |
BG63182B2 (bg) | Ваксиниране чрез специфични т- клетъчни популациисрещу заболявания в резултат на патогенни отговори |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22799088 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18286027 Country of ref document: US Ref document number: 2023561907 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280032494.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022799088 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022799088 Country of ref document: EP Effective date: 20231204 |